Novel proteins may target cystic fibrosis
Tuesday, 19 March, 2002
Sydney company Proteome Systems (PSL) has teamed up with US group Cystic Fibrosis Foundation Therapeutics to find drug targets to combat the disease.
Dr Jenny Harry, who heads PSL's discovery program, said the company planned to find novel proteins for the development of new drugs to treat cystic fibrosis.
"We are interested in identifying the protein expression patterns of sputum and lung secretions of CF individuals," she said. "Once these unique proteins are identified the next step is to develop drugs to prevent the action and reduce chronic CF lung disease.
"The constituents of mucus and submucosal gland secretions are important areas for understanding the pathology of the disease."
Cystic fibrosis sufferers carry a single faulty gene which affects their lungs, causing them to produce a sticky mucous that interferes with lung function. Heart-lung transplant is the more aggressive treatment for the disease, but it can be controlled by daily drug treatments.
Dr Robert Beall, president and CEO of Cystic Fibrosis Foundation Therapeutics, said PSL's technology platform and proteomics know-how, especially in mucin biology, would help the group achieve its goals.
Mucins are the major protein components in mucus.
"We may find targets based on the specific differences in sugar groups in CF patients," said PSL's cystic fibrosis project leader, Dr Andrew Sloane.
PSL's discovery program focuses on respiratory diseases such as tuberculosis and plans to apply its knowledge to the CF program.
New anti-clotting agent has its own 'off switch'
The anticoagulant's anti-clotting action can be rapidly stopped on demand, which could enable...
Genetic cause found for rare neurological disease
The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare movement...
Creating self-assembling capsules for drug delivery
Scientists have created nanosized capsules that could be used to deliver drugs and messenger RNA...
